Results 101 to 110 of about 35,256 (161)

[Bendamustine combined with anti-CD20 monoclonal antibody in the first-line treatment of older patients with indolent B-cell non-Hodgkin lymphoma: a multicenter retrospective study]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Qin SC, Miao Y, Zhang ZL, Zhang J, Shi YY, Miao YQ, Gu WY, Zheng WC, Jia ZX, Lin GQ, Ni HW, Xu XH, Xu M, Xie XY, Wang L, Zhuang Y, Zhang W, Liu P, Li JY, Shi WY.   +19 more
europepmc   +1 more source

Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study. [PDF]

Lancet Reg Health West Pac
Xu M, Shu J, Qian S, Guo J, Gong Y, Huang R, Wang S, Zhou Z, Yuan G, Huang M, Lin LE, Lou S, Song Y, Liu Q, Zhou H, Mei H, Hu Y.   +16 more
europepmc   +1 more source

Efficacy and safety of MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial. [PDF]

EClinicalMedicine
Shi Y, Zhou K, Zhou H, Qin Y, Jing H, Xiang Y, Wang Z, Wang Z, Zang A, Bai O, Li Z, Zhang H, Song Y, Liang J, Wei M.   +14 more
europepmc   +1 more source

Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product. [PDF]

Biologics, 2018
Singh SK, Pokalwar S, Bose S, Gupta S, Almal S, Ranbhor RS.   +5 more
europepmc   +1 more source

Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. [PDF]

Am J Transplant, 2019
Redfield RR, Jordan SC, Busque S, Vincenti F, Woodle ES, Desai N, Reed EF, Tremblay S, Zachary AA, Vo AA, Formica R, Schindler T, Tran H, Looney C, Jamois C, Green C, Morimoto A, Rajwanshi R, Schroeder A, Cascino MD, Brunetta P, Borie D.   +21 more
europepmc   +1 more source

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. [PDF]

Blood Adv, 2019
Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP.   +37 more
europepmc   +1 more source

Resolution of Q Fever-Associated Cryoglobulinemia With Anti-CD20 Monoclonal Antibody Treatment. [PDF]

J Investig Med High Impact Case Rep, 2017
Hawkins KL, Janoff EN, Janson RW.
europepmc   +1 more source

Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002 [PDF]

, 2020
openaire   +1 more source